These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 22872679)

  • 21. Long-Acting HIV-1 Fusion Inhibitory Peptides and their Mechanisms of Action.
    Wang C; Cheng S; Zhang Y; Ding Y; Chong H; Xing H; Jiang S; Li X; Ma L
    Viruses; 2019 Sep; 11(9):. PubMed ID: 31480738
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HIV-1 variants with a single-point mutation in the gp41 pocket region exhibiting different susceptibility to HIV fusion inhibitors with pocket- or membrane-binding domain.
    Lu L; Tong P; Yu X; Pan C; Zou P; Chen YH; Jiang S
    Biochim Biophys Acta; 2012 Dec; 1818(12):2950-7. PubMed ID: 22867851
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Maraviroc and other HIV-1 entry inhibitors exhibit a class-specific redistribution effect that results in increased extracellular viral load.
    Kramer VG; Schader SM; Oliveira M; Colby-Germinario SP; Donahue DA; Singhroy DN; Tressler R; Sloan RD; Wainberg MA
    Antimicrob Agents Chemother; 2012 Aug; 56(8):4154-60. PubMed ID: 22615275
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enfuvirtide resistance mutations: impact on human immunodeficiency virus envelope function, entry inhibitor sensitivity, and virus neutralization.
    Reeves JD; Lee FH; Miamidian JL; Jabara CB; Juntilla MM; Doms RW
    J Virol; 2005 Apr; 79(8):4991-9. PubMed ID: 15795284
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of the envelope genetic context in the development of enfuvirtide resistance in human immunodeficiency virus type 1-infected patients.
    Labrosse B; Morand-Joubert L; Goubard A; Rochas S; Labernardière JL; Pacanowski J; Meynard JL; Hance AJ; Clavel F; Mammano F
    J Virol; 2006 Sep; 80(17):8807-19. PubMed ID: 16912327
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A low-molecular-weight entry inhibitor of both CCR5- and CXCR4-tropic strains of human immunodeficiency virus type 1 targets a novel site on gp41.
    Murray EJ; Leaman DP; Pawa N; Perkins H; Pickford C; Perros M; Zwick MB; Butler SL
    J Virol; 2010 Jul; 84(14):7288-99. PubMed ID: 20427524
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HIV entry inhibitors: mechanisms of action and resistance pathways.
    Briz V; Poveda E; Soriano V
    J Antimicrob Chemother; 2006 Apr; 57(4):619-27. PubMed ID: 16464888
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of a novel fusion inhibitor against T-20-resistant HIV-1.
    Oishi S; Ito S; Nishikawa H; Tanaka M; Ohno H; Otaka A; Izumi K; Kodama E; Matsuoka M; Fujii N
    Adv Exp Med Biol; 2009; 611():389-91. PubMed ID: 19400237
    [No Abstract]   [Full Text] [Related]  

  • 29. Capture of an early fusion-active conformation of HIV-1 gp41.
    Furuta RA; Wild CT; Weng Y; Weiss CD
    Nat Struct Biol; 1998 Apr; 5(4):276-9. PubMed ID: 9546217
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Short-peptide fusion inhibitors with high potency against wild-type and enfuvirtide-resistant HIV-1.
    Chong H; Yao X; Qiu Z; Sun J; Zhang M; Waltersperger S; Wang M; Liu SL; Cui S; He Y
    FASEB J; 2013 Mar; 27(3):1203-13. PubMed ID: 23233535
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Full fusion competence rescue of the enfuvirtide resistant HIV-1 gp41 genotype (43D) by a prevalent polymorphism (137K).
    Tolstrup M; Selzer-Plön J; Laursen AL; Bertelsen L; Gerstoft J; Duch M; Pedersen FS; Ostergaard L
    AIDS; 2007 Feb; 21(4):519-21. PubMed ID: 17301572
    [No Abstract]   [Full Text] [Related]  

  • 32. HIV-1 gp41-targeting fusion inhibitory peptides enhance the gp120-targeting protein-mediated inactivation of HIV-1 virions.
    Qi Q; Wang Q; Chen W; Du L; Dimitrov DS; Lu L; Jiang S
    Emerg Microbes Infect; 2017 Jun; 6(6):e59. PubMed ID: 28634358
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The M-T hook structure increases the potency of HIV-1 fusion inhibitor sifuvirtide and overcomes drug resistance.
    Chong H; Yao X; Qiu Z; Sun J; Qiao Y; Zhang M; Wang M; Cui S; He Y
    J Antimicrob Chemother; 2014 Oct; 69(10):2759-69. PubMed ID: 24908047
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HIV-1 resistance mechanism to an electrostatically constrained peptide fusion inhibitor that is active against T-20-resistant strains.
    Shimane K; Kawaji K; Miyamoto F; Oishi S; Watanabe K; Sakagami Y; Fujii N; Shimura K; Matsuoka M; Kaku M; Sarafianos SG; Kodama EN
    Antimicrob Agents Chemother; 2013 Aug; 57(8):4035-8. PubMed ID: 23689710
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The current progress in the development of HIV-1 fusion inhibitors].
    Shi WG; Jia QY; Liu KL
    Yao Xue Xue Bao; 2010 Feb; 45(2):184-93. PubMed ID: 21351428
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular mechanism of HIV-1 resistance to sifuvirtide, a clinical trial-approved membrane fusion inhibitor.
    Yu D; Ding X; Liu Z; Wu X; Zhu Y; Wei H; Chong H; Cui S; He Y
    J Biol Chem; 2018 Aug; 293(33):12703-12718. PubMed ID: 29929981
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Altered bystander apoptosis induction and pathogenesis of enfuvirtide-resistant HIV type 1 Env mutants.
    Garg H; Joshi A; Blumenthal R
    AIDS Res Hum Retroviruses; 2009 Aug; 25(8):811-7. PubMed ID: 19619009
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Updating the use of synthetic peptides as inhibitors of HIV-1 entry.
    Gómara MJ; Haro I
    Curr Med Chem; 2014 Apr; 21(10):1188-200. PubMed ID: 23931277
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Conjugation of a nonspecific antiviral sapogenin with a specific HIV fusion inhibitor: a promising strategy for discovering new antiviral therapeutics.
    Wang C; Lu L; Na H; Li X; Wang Q; Jiang X; Xu X; Yu F; Zhang T; Li J; Zhang Z; Zheng B; Liang G; Cai L; Jiang S; Liu K
    J Med Chem; 2014 Sep; 57(17):7342-54. PubMed ID: 25156906
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HIV ENV glycoprotein-mediated bystander apoptosis depends on expression of the CCR5 co-receptor at the cell surface and ENV fusogenic activity.
    Joshi A; Nyakeriga AM; Ravi R; Garg H
    J Biol Chem; 2011 Oct; 286(42):36404-13. PubMed ID: 21859712
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.